The WT1 Trio vaccine, which includes a helper peptide (WT1-332), was administered in combination in order to activate WT1-specific CD4+ T helper lymphocytes and enhance WT1-specific anti-tumor cellular immune responses. This evidence concerns the gene WT1 and neoplasm.